Pacific Biosciences (PACB) Canaccord Bus Tour presentation summary

Strategic priorities and growth initiatives

• Focus on executing SPRQ-Nx chemistry rollout and launching a high-throughput platform.

• Restructuring to align marketing and commercial teams with clinical and commercial accounts.

• Expansion into clinical and commercial markets, aiming for cash flow breakeven by 2028.

• Emphasis on enabling discovery and AI biological models.

Product and technology advancements

• SPRQ-Nx chemistry launched in May 2026, with ~50% of installed base opted in by Q3.

• U.S. list price per genome reduced to $345, enhancing competitiveness for large-scale projects.

• Multi-use SMRT cells drive lower costs and higher throughput.

• High-throughput platform launch planned to further expand capabilities.

AI and data partnerships

• Largest project to date: Trillion Gene Atlas with Basecamp Research, targeting over 100 million samples.

• Long-read sequencing data positioned as essential for training advanced AI models.

• Collaborations with NVIDIA and Anthropic to advance generative biology.

• Efforts underway to make data more accessible and licensable.